{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:36:25Z","timestamp":1790138185881,"version":"4.0.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T00:00:00Z","timestamp":1747440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T00:00:00Z","timestamp":1747440000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2019-01887"],"award-info":[{"award-number":["2019-01887"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2013-07434"],"award-info":[{"award-number":["2013-07434"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007308","name":"Sveriges L\u00e4karf\u00f6rbund","doi-asserted-by":"publisher","award":["SLS-939751"],"award-info":[{"award-number":["SLS-939751"]}],"id":[{"id":"10.13039\/501100007308","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Mental Health Initiative in Stress and Trauma Chair at the University of Calgary"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol."],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Post-traumatic stress disorder (PTSD) is a severe mental health disorder with limited treatment options. Gold standard treatment includes cognitive behavioral therapies (CBT) that incorporate exposure to traumatic memories to facilitate extinction. CBT can be effective in PTSD, but effects are incomplete and symptoms are prone to spontaneous return. Pharmacologically facilitating fear extinction could potentiate the effects of exposure-based therapy. Here, we explored whether targeting the endocannabinoid (eCB) system, a neuromodulatory system critically involved in fear extinction, would promote the efficacy of exposure-based CBT. Specifically, we tested the effects of elevating the eCB ligand anandamide (AEA) via inhibition of its main degradative enzyme, fatty acid amide hydrolase (FAAH). In this double-blind, placebo-controlled study, patients with PTSD (<jats:italic>N<\/jats:italic>\u2009=\u2009100; 85 women) were randomized to the FAAH inhibitor (FAAHi) JNJ-42165279 (25\u2009mg b.i.d.) or placebo for 12 weeks. In weeks 5\u201312, all participants completed an internet-delivered CBT that included exposure-based modules. The primary outcome was clinician-assessed PTSD symptom severity (CAPS-5). Secondary outcomes included self-reported symptoms of PTSD, depression, anxiety, and sleep quality. Blood samples were taken to measure levels of drug and eCBs. Overall, PTSD symptoms improved over time. While FAAHi increased AEA levels, there was no effect of FAAHi on PTSD symptoms or any secondary measure. FAAHi combined with internet-delivered CBT did not improve PTSD symptoms to a greater extent than internet-delivered CBT alone. Thus, FAAH inhibition does not appear to be a suitable adjunct treatment for enhancing CBT in PTSD. This study was registered as Eudra-CT 2020-001965-36.<\/jats:p>","DOI":"10.1038\/s41386-025-02128-w","type":"journal-article","created":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T12:11:19Z","timestamp":1747483879000},"page":"1564-1572","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["The efficacy of elevating anandamide via inhibition of fatty acid amide hydrolase (FAAH) combined with internet-delivered cognitive behavioral therapy in the treatment of post-traumatic stress disorder: a randomized, placebo-controlled clinical trial"],"prefix":"10.1038","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0645-4869","authenticated-orcid":false,"given":"Leah M.","family":"Mayo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emelie","family":"Gauffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin N.","family":"Petrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6865-5893","authenticated-orcid":false,"given":"Ryann","family":"Tansey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4974-4815","authenticated-orcid":false,"given":"Raegan","family":"Mazurka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6678-0570","authenticated-orcid":false,"given":"Connor J.","family":"Haggarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine R.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilda","family":"Engelbrektsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Aminoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anisja","family":"H\u00fchne-Landgraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3417-8977","authenticated-orcid":false,"given":"Mark E.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darrel J.","family":"Pemberton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Fredlund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"\u00d6stman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Karlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"L\u00f6fberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Pietrzak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1758-2206","authenticated-orcid":false,"given":"Andrea Johansson","family":"Capusan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew N.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Heilig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,17]]},"reference":[{"key":"2128_CR1","doi-asserted-by":"publisher","DOI":"10.1080\/20008198.2017.1353383","volume":"8","author":"RC Kessler","year":"2017","unstructured":"Kessler RC, Aguilar-Gaxiola S, Alonso J, Benjet C, Bromet EJ, Cardoso G. Trauma and PTSD in the WHO World Mental Health Surveys. Eur J Psychotraumatol. 2017;8:1353383. https:\/\/doi.org\/10.1080\/20008198.2017.1353383.","journal-title":"Eur J Psychotraumatol"},{"key":"2128_CR2","unstructured":"Foa EB, Keane TM, Friedman MJ. Effective treatments for PTSD: practice guidelines from the international society for traumatic stress studies. New York, NY: The Guilford Press; 2000:xii, pp. 388."},{"key":"2128_CR3","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/S1077-7229(03)80005-6","volume":"10","author":"EA Hembree","year":"2003","unstructured":"Hembree EA, Rauch SAM, Foa EB. Beyond the manual: the insider\u2019s guide to prolonged exposure therapy for PTSD. Cogn Behav Pract. 2003;10:22\u201330. https:\/\/doi.org\/10.1016\/S1077-7229(03)80005-6.","journal-title":"Cogn Behav Pract"},{"key":"2128_CR4","doi-asserted-by":"publisher","first-page":"CD003388","DOI":"10.1002\/14651858.CD003388.pub4","volume":"2013","author":"JI Bisson","year":"2013","unstructured":"Bisson JI, Roberts NP, Andrew M, Cooper R, Lewis C. Psychological therapies for chronic post-traumatic stress disorder (PTSD) in adults. Cochrane Database Syst Rev. 2013;2013:CD003388. https:\/\/doi.org\/10.1002\/14651858.CD003388.pub4.","journal-title":"Cochrane Database Syst Rev"},{"key":"2128_CR5","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1002\/jts.21945","volume":"27","author":"JI Ruzek","year":"2014","unstructured":"Ruzek JI, Eftekhari A, Rosen CS, Crowley JJ, Kuhn E, Foa EB. Factors related to clinician attitudes toward prolonged exposure therapy for PTSD. J Trauma Stress. 2014;27:423\u20139. https:\/\/doi.org\/10.1002\/jts.21945.","journal-title":"J Trauma Stress"},{"key":"2128_CR6","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3390\/jcm5110105","volume":"5","author":"CL Lancaster","year":"2016","unstructured":"Lancaster CL, Teeters JB, Gros DF, Back SE. Posttraumatic stress disorder: overview of evidence-based assessment and treatment. J Clin Med. 2016;5:105. https:\/\/doi.org\/10.3390\/jcm5110105.","journal-title":"J Clin Med"},{"key":"2128_CR7","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1001\/jamapsychiatry.2018.3412","volume":"76","author":"SAM Rauch","year":"2019","unstructured":"Rauch SAM, Kim HM, Powell C, Tuerk PW, Simon NM, Acierno R. Efficacy of prolonged exposure therapy, sertraline hydrochloride, and their combination among combat veterans with posttraumatic stress disorder: a randomized clinical trial. JAMA Psychiatry. 2019;76:117\u201326. https:\/\/doi.org\/10.1001\/jamapsychiatry.2018.3412.","journal-title":"JAMA Psychiatry"},{"key":"2128_CR8","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/npp.2017.162","volume":"43","author":"MN Hill","year":"2018","unstructured":"Hill MN, Campolongo P, Yehuda R, Patel S. Integrating endocannabinoid signaling and cannabinoids into the biology and treatment of posttraumatic stress disorder. Neuropsychopharmacology. 2018;43:80\u2013102. https:\/\/doi.org\/10.1038\/npp.2017.162.","journal-title":"Neuropsychopharmacology"},{"key":"2128_CR9","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.biopsych.2021.07.019","volume":"91","author":"LM Mayo","year":"2022","unstructured":"Mayo LM, Rabinak CA, Hill MN, Heilig M. Targeting the endocannabinoid system in the treatment of posttraumatic stress disorder: a promising case of preclinical-clinical translation? Biol Psychiatry. 2022;91:262\u201372. https:\/\/doi.org\/10.1016\/j.biopsych.2021.07.019.","journal-title":"Biol Psychiatry"},{"key":"2128_CR10","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1126\/science.1470919","volume":"258","author":"WA Devane","year":"1992","unstructured":"Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258:1946\u20139. https:\/\/doi.org\/10.1126\/science.1470919.","journal-title":"Science"},{"key":"2128_CR11","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/346561a0","volume":"346","author":"LA Matsuda","year":"1990","unstructured":"Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990;346:561\u20134. https:\/\/doi.org\/10.1038\/346561a0.","journal-title":"Nature"},{"key":"2128_CR12","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/365061a0","volume":"365","author":"S Munro","year":"1993","unstructured":"Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365:61\u201365. https:\/\/doi.org\/10.1038\/365061a0.","journal-title":"Nature"},{"key":"2128_CR13","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/0006-2952(95)00109-d","volume":"50","author":"R Mechoulam","year":"1995","unstructured":"Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharm. 1995;50:83\u201390. https:\/\/doi.org\/10.1016\/0006-2952(95)00109-d.","journal-title":"Biochem Pharm"},{"key":"2128_CR14","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/npp.2015.166","volume":"41","author":"M Morena","year":"2016","unstructured":"Morena M, Patel S, Bains JS, Hill MN. Neurobiological interactions between stress and the endocannabinoid system. Neuropsychopharmacology. 2016;41:80\u2013102. https:\/\/doi.org\/10.1038\/npp.2015.166.","journal-title":"Neuropsychopharmacology"},{"key":"2128_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2021.108626","volume":"195","author":"GN Petrie","year":"2021","unstructured":"Petrie GN, Nastase AS, Aukema RJ, Hill MN. Endocannabinoids, cannabinoids and the regulation of anxiety. Neuropharmacology. 2021;195:108626. https:\/\/doi.org\/10.1016\/j.neuropharm.2021.108626.","journal-title":"Neuropharmacology"},{"key":"2128_CR16","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1021\/ja01062a046","volume":"86","author":"Y Gaoni","year":"1964","unstructured":"Gaoni Y, Mechoulam R. Isolation, structure, and partial synthesis of an active constituent of hashish. J Am Chem Soc. 1964;86:1646\u20137. https:\/\/doi.org\/10.1021\/ja01062a046.","journal-title":"J Am Chem Soc"},{"key":"2128_CR17","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3109\/07853890.2016.1145794","volume":"48","author":"RJ Schrot","year":"2016","unstructured":"Schrot RJ, Hubbard JR. Cannabinoids: medical implications. Ann Med. 2016;48:128\u201341. https:\/\/doi.org\/10.3109\/07853890.2016.1145794.","journal-title":"Ann Med"},{"key":"2128_CR18","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S2215-0366(18)30427-9","volume":"6","author":"DC D'Souza","year":"2019","unstructured":"D'Souza DC, Cortes-Briones J, Creatura G, Bluez G, Thurnauer H, Deaso E. Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: a double-blind, placebo-controlled, parallel group, phase 2a single-site randomised controlled trial. Lancet Psychiatry. 2019;6:35\u201345. https:\/\/doi.org\/10.1016\/S2215-0366(18)30427-9.","journal-title":"Lancet Psychiatry"},{"key":"2128_CR19","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.biopsych.2019.07.034","volume":"87","author":"LM Mayo","year":"2020","unstructured":"Mayo LM, Asratian A, Lind\u00e9 J, Morena M, Haataja R, Hammar V. Elevated anandamide, enhanced recall of fear extinction, and attenuated stress responses following inhibition of fatty acid amide hydrolase: a randomized, controlled experimental medicine trial. Biol Psychiatry. 2020;87:538\u201347. https:\/\/doi.org\/10.1016\/j.biopsych.2019.07.034.","journal-title":"Biol Psychiatry"},{"key":"2128_CR20","doi-asserted-by":"publisher","first-page":"7379","DOI":"10.1073\/pnas.1016167108","volume":"108","author":"X Min","year":"2011","unstructured":"Min X, Thibault ST, Porter AC, Gustin DJ, Carlson TJ, Xu H. Discovery and molecular basis of potent noncovalent inhibitors of fatty acid amide hydrolase (FAAH). Proc Natl Acad Sci USA. 2011;108:7379\u201384. https:\/\/doi.org\/10.1073\/pnas.1016167108.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2128_CR21","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1038\/s41386-020-00888-1","volume":"46","author":"ME Schmidt","year":"2021","unstructured":"Schmidt ME, Liebowitz MR, Stein MB, Grunfeld J, Van Hove I, Simmons WK. The effects of inhibition of fatty acid amide hydrolase (FAAH) by JNJ-42165279 in social anxiety disorder: a double-blind, randomized, placebo-controlled proof-of-concept study. Neuropsychopharmacology. 2021;46:1004\u201310. https:\/\/doi.org\/10.1038\/s41386-020-00888-1.","journal-title":"Neuropsychopharmacology"},{"key":"2128_CR22","doi-asserted-by":"publisher","first-page":"9371","DOI":"10.1073\/pnas.161191698","volume":"98","author":"BF Cravatt","year":"2001","unstructured":"Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK, Martin BR. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci USA. 2001;98:9371\u20136. https:\/\/doi.org\/10.1073\/pnas.161191698.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2128_CR23","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/mp.2012.72","volume":"18","author":"O Gunduz-Cinar","year":"2013","unstructured":"Gunduz-Cinar O, MacPherson KP, Cinar R, Gamble-George J, Sugden K, Williams B. Convergent translational evidence of a role for anandamide in amygdala-mediated fear extinction, threat processing and stress-reactivity. Mol Psychiatry. 2013;18:813\u201323. https:\/\/doi.org\/10.1038\/mp.2012.72.","journal-title":"Mol Psychiatry"},{"key":"2128_CR24","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1038\/sj.npp.1301224","volume":"32","author":"SA Varvel","year":"2007","unstructured":"Varvel SA, Wise LE, Niyuhire F, Cravatt BF, Lichtman AH. Inhibition of fatty-acid amide hydrolase accelerates acquisition and extinction rates in a spatial memory task. Neuropsychopharmacology. 2007;32:1032\u201341. https:\/\/doi.org\/10.1038\/sj.npp.1301224.","journal-title":"Neuropsychopharmacology"},{"key":"2128_CR25","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1111\/acer.13210","volume":"40","author":"PA Spagnolo","year":"2016","unstructured":"Spagnolo PA, Ramchandani VA, Schwandt ML, Kwako LE, George DT, Mayo LM. FAAH gene variation moderates stress response and symptom severity in patients with posttraumatic stress disorder and comorbid alcohol dependence. Alcohol Clin Exp Res. 2016;40:2426\u201334. https:\/\/doi.org\/10.1111\/acer.13210.","journal-title":"Alcohol Clin Exp Res"},{"key":"2128_CR26","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.invent.2014.03.002","volume":"1","author":"D Ivarsson","year":"2014","unstructured":"Ivarsson D, Blom M, Hesser H. Guided internet-delivered cognitive behavior therapy for post-traumatic stress disorder: a randomized controlled trial. Internet Interventions. 2014;1:33\u201340. https:\/\/doi.org\/10.1016\/j.invent.2014.03.002.","journal-title":"Internet Interventions"},{"key":"2128_CR27","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1002\/da.22533","volume":"33","author":"M Sijbrandij","year":"2016","unstructured":"Sijbrandij M, Kunovski I, Cuijpers P. Effectiveness of internet-delivered cognitive behavioral therapy for posttraumatic stress disorder: a systematic review and meta-analysis. Depress Anxiety. 2016;33:783\u201391. https:\/\/doi.org\/10.1002\/da.22533.","journal-title":"Depress Anxiety"},{"key":"2128_CR28","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/S2215-0366(23)00226-2","volume":"10","author":"JI Bisson","year":"2023","unstructured":"Bisson JI, Kitchiner NJ, Lewis C, Roberts NP. Guided, internet-based interventions for post-traumatic stress disorder. Lancet Psychiatry. 2023;10:577\u20139. https:\/\/doi.org\/10.1016\/S2215-0366(23)00226-2.","journal-title":"Lancet Psychiatry"},{"key":"2128_CR29","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1037\/cps0000111","volume":"30","author":"SR Forkus","year":"2023","unstructured":"Forkus SR, Raudales AM, Rafiuddin HS, Weiss NH, Messman BA, Contractor AA. The posttraumatic stress disorder (PTSD) checklist for DSM-5: a systematic review of existing psychometric evidence. Clin Psychol. 2023;30:110\u201321. https:\/\/doi.org\/10.1037\/cps0000111.","journal-title":"Clin Psychol"},{"key":"2128_CR30","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1021\/acsmedchemlett.5b00353","volume":"6","author":"JM Keith","year":"2015","unstructured":"Keith JM, Jones WM, Tichenor M, Liu J, Seierstad M, Palmer JA. Preclinical characterization of the FAAH inhibitor JNJ-42165279. ACS Med Chem Lett. 2015;6:1204\u20138. https:\/\/doi.org\/10.1021\/acsmedchemlett.5b00353.","journal-title":"ACS Med Chem Lett"},{"key":"2128_CR31","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/cts.12548","volume":"11","author":"A Postnov","year":"2018","unstructured":"Postnov A, Schmidt ME, Pemberton DJ, de Hoon J, van Hecken A, van den Boer M. Fatty acid amide hydrolase inhibition by JNJ-42165279: a multiple-ascending dose and a positron emission tomography study in healthy volunteers. Clin Transl Sci. 2018;11:397\u2013404. https:\/\/doi.org\/10.1111\/cts.12548.","journal-title":"Clin Transl Sci"},{"key":"2128_CR32","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/s0272-7358(03)00035-7","volume":"23","author":"AG Harvey","year":"2003","unstructured":"Harvey AG, Bryant RA, Tarrier N. Cognitive behaviour therapy for posttraumatic stress disorder. Clin Psychol Rev. 2003;23:501\u201322. https:\/\/doi.org\/10.1016\/s0272-7358(03)00035-7.","journal-title":"Clin Psychol Rev"},{"key":"2128_CR33","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1176\/appi.ajp.158.12.2043","volume":"158","author":"B Krakow","year":"2001","unstructured":"Krakow B, Johnston L, Melendrez D, Hollifield M, Warner TD, Chavez-Kennedy D. An open-label trial of evidence-based cognitive behavior therapy for nightmares and insomnia in crime victims with PTSD. Am J Psychiatry. 2001;158:2043\u20137. https:\/\/doi.org\/10.1176\/appi.ajp.158.12.2043.","journal-title":"Am J Psychiatry"},{"key":"2128_CR34","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1002\/wps.21088","volume":"22","author":"E Hedman-Lagerl\u00f6f","year":"2023","unstructured":"Hedman-Lagerl\u00f6f E, Carlbring P, Sv\u00e4rdman F, Riper H, Cuijpers P, Andersson G. Therapist-supported Internet-based cognitive behaviour therapy yields similar effects as face-to-face therapy for psychiatric and somatic disorders: an updated systematic review and meta-analysis. World Psychiatry. 2023;22:305\u201314. https:\/\/doi.org\/10.1002\/wps.21088.","journal-title":"World Psychiatry"},{"key":"2128_CR35","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/0165-1781(89)90047-4","volume":"28","author":"DJ Buysse","year":"1989","unstructured":"Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28:193\u2013213. https:\/\/doi.org\/10.1016\/0165-1781(89)90047-4.","journal-title":"Psychiatry Res"},{"key":"2128_CR36","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1037\/pas0000486","volume":"30","author":"FW Weathers","year":"2018","unstructured":"Weathers FW, Bovin MJ, Lee DJ, Sloan DM, Schnurr PP, Kaloupek DG. The clinician-administered PTSD scale for DSM\u20135 (CAPS-5): development and initial psychometric evaluation in military veterans. Psychol Assess. 2018;30:383\u201395. https:\/\/doi.org\/10.1037\/pas0000486.","journal-title":"Psychol Assess"},{"key":"2128_CR37","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1002\/jts.22059","volume":"28","author":"CA Blevins","year":"2015","unstructured":"Blevins CA, Weathers FW, Davis MT, Witte TK, Domino JL. The posttraumatic stress disorder checklist for DSM-5 (PCL-5): development and initial psychometric evaluation. J Trauma Stress. 2015;28:489\u201398. https:\/\/doi.org\/10.1002\/jts.22059.","journal-title":"J Trauma Stress"},{"key":"2128_CR38","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/j.1600-0447.1994.tb01480.x","volume":"89","author":"P Svanborg","year":"1994","unstructured":"Svanborg P, Asberg M. A new self-rating scale for depression and anxiety states based on the Comprehensive Psychopathological Rating Scale. Acta Psychiatr Scand. 1994;89:21\u201328. https:\/\/doi.org\/10.1111\/j.1600-0447.1994.tb01480.x.","journal-title":"Acta Psychiatr Scand"},{"key":"2128_CR39","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1002\/rcm.7277","volume":"29","author":"M Qi","year":"2015","unstructured":"Qi M, Morena M, Vecchiarelli HA, Hill MN, Schriemer DC. A robust capillary liquid chromatography\/tandem mass spectrometry method for quantitation of neuromodulatory endocannabinoids. Rapid Commun Mass Spectrom. 2015;29:1889\u201397. https:\/\/doi.org\/10.1002\/rcm.7277.","journal-title":"Rapid Commun Mass Spectrom"},{"key":"2128_CR40","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1017\/S0033291721001641","volume":"51","author":"N Morina","year":"2021","unstructured":"Morina N, Hoppen TH, Kip A. Study quality and efficacy of psychological interventions for posttraumatic stress disorder: a meta-analysis of randomized controlled trials. Psychol Med. 2021;51:1260\u201370. https:\/\/doi.org\/10.1017\/S0033291721001641.","journal-title":"Psychol Med"},{"key":"2128_CR41","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s11126-017-9522-y","volume":"89","author":"EA Stefanovics","year":"2018","unstructured":"Stefanovics EA, Rosenheck RA, Jones KM, Huang G, Krystal JH. Minimal clinically important differences (MCID) in assessing outcomes of post-traumatic stress disorder. Psychiatr Q. 2018;89:141\u201355. https:\/\/doi.org\/10.1007\/s11126-017-9522-y.","journal-title":"Psychiatr Q"},{"key":"2128_CR42","doi-asserted-by":"publisher","first-page":"18333","DOI":"10.1073\/pnas.1420285111","volume":"111","author":"M Morena","year":"2014","unstructured":"Morena M, Roozendaal B, Trezza V, Ratano P, Peloso A, Hauer D. Endogenous cannabinoid release within prefrontal-limbic pathways affects memory consolidation of emotional training. Proc Natl Acad Sci. 2014;111:18333\u20138. https:\/\/doi.org\/10.1073\/pnas.1420285111.","journal-title":"Proc Natl Acad Sci"},{"key":"2128_CR43","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/nature00839","volume":"418","author":"G Marsicano","year":"2002","unstructured":"Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG. The endogenous cannabinoid system controls extinction of aversive memories. Nature. 2002;418:530\u20134. https:\/\/doi.org\/10.1038\/nature00839.","journal-title":"Nature"},{"key":"2128_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41386-024-02001-2","volume":"50","author":"ME Klein","year":"2024","unstructured":"Klein ME, Bangerter A, Halter RJ, Cooper K, Aguilar Z, Canuso CM, et al. Efficacy and safety of JNJ-42165279, a fatty acid amide hydrolase inhibitor, in adolescents and adults with autism spectrum disorder: a randomized, phase 2, placebo-controlled study. Neuropsychopharmacology. 2024;50:1\u20138. https:\/\/doi.org\/10.1038\/s41386-024-02001-2.","journal-title":"Neuropsychopharmacology"},{"key":"2128_CR45","unstructured":"Jazz pharmaceuticals provides update on phase 2 trial of investigational JZP150 in adult patients with post-traumatic stress disorder. Jazz Pharmaceuticals plc. 2024. https:\/\/investor.jazzpharma.com\/news-releases\/news-release-details\/jazz-pharmaceuticals-provides-update-phase-2-trial\/."},{"key":"2128_CR46","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1007\/s00213-020-05499-8","volume":"237","author":"CA Rabinak","year":"2020","unstructured":"Rabinak CA, Blanchette A, Zabik NL, Peters C, Marusak HA, Iadipaolo A. Cannabinoid modulation of corticolimbic activation to threat in trauma-exposed adults: a preliminary study. Psychopharmacology. 2020;237:1813\u201326. https:\/\/doi.org\/10.1007\/s00213-020-05499-8.","journal-title":"Psychopharmacology"},{"key":"2128_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.nlm.2023.107758","volume":"201","author":"NL Zabik","year":"2023","unstructured":"Zabik NL, Rabinak CA, Peters CA, Iadipaolo A. Cannabinoid modulation of corticolimbic activation during extinction learning and fear renewal in adults with posttraumatic stress disorder. Neurobiol Learn Mem. 2023;201:107758. https:\/\/doi.org\/10.1016\/j.nlm.2023.107758.","journal-title":"Neurobiol Learn Mem"},{"key":"2128_CR48","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.biopsych.2024.07.010","volume":"97","author":"JL Maples-Keller","year":"2025","unstructured":"Maples-Keller JL, Watkins L, Hellman N, Phillips NL, Rothbaum BO. Treatment approaches for posttraumatic stress disorder derived from basic research on fear extinction. Biol Psychiatry. 2025;97:382\u201391. https:\/\/doi.org\/10.1016\/j.biopsych.2024.07.010.","journal-title":"Biol Psychiatry"},{"key":"2128_CR49","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/s41386-020-00936-w","volume":"46","author":"MP Paulus","year":"2021","unstructured":"Paulus MP, Stein MB, Simmons AN, Risbrough VB, Halter R, Chaplan SR. The effects of FAAH inhibition on the neural basis of anxiety-related processing in healthy male subjects: a randomized clinical trial. Neuropsychopharmacology. 2021;46:1011\u20139. https:\/\/doi.org\/10.1038\/s41386-020-00936-w.","journal-title":"Neuropsychopharmacology"},{"key":"2128_CR50","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.biopsych.2020.01.015","volume":"88","author":"G Bedse","year":"2020","unstructured":"Bedse G, Hill MN, Patel S. 2-Arachidonoylglycerol Modulation of Anxiety and Stress Adaptation: From Grass Roots to Novel Therapeutics. Biol Psychiatry. 2020;88:520\u201330. https:\/\/doi.org\/10.1016\/j.biopsych.2020.01.015.","journal-title":"Biol Psychiatry"},{"key":"2128_CR51","doi-asserted-by":"publisher","DOI":"10.1101\/2024.01.30.577847","author":"LE Rosas-Vidal","year":"2024","unstructured":"Rosas-Vidal LE, Naskar S, Mayo LM, Perini I, Altemus M, Engelbrektsson H, et al. Prefrontal correlates of fear generalization during endocannabinoid depletion. bioRxiv. 2024. https:\/\/doi.org\/10.1101\/2024.01.30.577847.","journal-title":"bioRxiv"},{"key":"2128_CR52","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/nn.2616","volume":"13","author":"JE Schlosburg","year":"2010","unstructured":"Schlosburg JE, Blankman JL, Long JZ, Nomura DK, Pan B, Kinsey SG. Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system. Nat Neurosci. 2010;13:1113\u20139. https:\/\/doi.org\/10.1038\/nn.2616.","journal-title":"Nat Neurosci"},{"key":"2128_CR53","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.bbr.2015.12.005","volume":"300","author":"ME Bowers","year":"2016","unstructured":"Bowers ME, Ressler KJ. Sex-dependence of anxiety-like behavior in cannabinoid receptor 1 (Cnr1) knockout mice. Behav Brain Res. 2016;300:65\u201369. https:\/\/doi.org\/10.1016\/j.bbr.2015.12.005.","journal-title":"Behav Brain Res"},{"key":"2128_CR54","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1111\/bph.15341","volume":"178","author":"M Morena","year":"2021","unstructured":"Morena M, Nastase AS, Santori A, Cravatt BF, Shansky RM, Hill MN. Sex-dependent effects of endocannabinoid modulation of conditioned fear extinction in rats. Br J Pharm. 2021;178:983\u201396. https:\/\/doi.org\/10.1111\/bph.15341.","journal-title":"Br J Pharm"},{"key":"2128_CR55","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1089\/can.2023.0150","volume":"8","author":"CP Wood","year":"2023","unstructured":"Wood CP, Avalos B, Alvarez C, DiPatrizio NV. A sexually dimorphic role for intestinal cannabinoid receptor subtype-1 in the behavioral expression of anxiety. Cannabis Cannabinoid Res. 2023;8:1045\u201359. https:\/\/doi.org\/10.1089\/can.2023.0150.","journal-title":"Cannabis Cannabinoid Res"},{"key":"2128_CR56","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1038\/s41386-023-01650-z","volume":"48","author":"KA Huckleberry","year":"2023","unstructured":"Huckleberry KA, Calitri R, Li AJ, Mejdell M, Singh A, Bhutani V. CB1R blockade unmasks TRPV1-mediated contextual fear generalization in female, but not male rats. Neuropsychopharmacol. 2023;48:1500\u20138. https:\/\/doi.org\/10.1038\/s41386-023-01650-z.","journal-title":"Neuropsychopharmacol"},{"key":"2128_CR57","doi-asserted-by":"publisher","unstructured":"Rajasekera TA, Joseph A, Pan H, Dreyfuss JM, Fida D, Wilson J. Sex differences in endocannabinoid and inflammatory markers associated with posttraumatic stress disorder. 2025. https:\/\/doi.org\/10.1101\/2025.01.13.25320467.","DOI":"10.1101\/2025.01.13.25320467"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41386-025-02128-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-025-02128-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-025-02128-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T08:39:01Z","timestamp":1754901541000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41386-025-02128-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,17]]},"references-count":57,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["2128"],"URL":"https:\/\/doi.org\/10.1038\/s41386-025-02128-w","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,17]]},"assertion":[{"value":"30 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MES and DJP were full-time employees of Janssen Pharmaceutica NV during the execution of the study. MH received clinical trial materials and funding from Janssen Pharmaceutica NV for work related to this trial. MH has also received consulting fees, research support or other compensation from Indivior, Camurus, Molteni, BrainsWay, Aelis Farma, and Lundbeck. AJC has received consulting fees from Indivior, Camurus, Lundbeck, and DNEPharma. LMM has received consulting fees from Synendos Therapeutics. All other authors declare no biomedical financial interest or potential conflicts of interest. Dr. Leah Mayo is the NPP Social Media Editor and Drs. Matthew Hill and Markus Heilig are NPP Senior Editors.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}